跳至主要内容
临床试验/CTRI/2024/03/064543
CTRI/2024/03/064543尚未招募2 期

Evaluating Clinical Efficacy Of Add On Effect Of Basti In Non-Alcoholic Fatty Liver Disease Based On Sonographic Findings. - NI

All India Institute Of Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Previously diagnosed and newly diagnosed case of NAFLD (fatty liver grade 1 or 2) confirmed by
  • Sonography (USG Or Fibroscan)
  • 2.Grade 1 & Grade 2 NAFLD in USG Or F0 to F2 Less Than 10kPa Score,CAP Score -S1 248-260db per m,S2
  • 260-290 db per m,IQR per M-30 Percent or less in Fibroscan.
  • 3.Patients willing to participate in the clinical trial.

排除标准

  • 1.Patent having NASH/NAFLD associated with Metabolic diseases
  • 2. Patients having NAFLD Grade 3 Or More
  • 3. Patients with Type 2 diabetes
  • 4. Known case of Hypertension
  • 5. Known case of hypothyroidism or hyperthyroidism
  • 6. Patients having BMI Greater than 30,
  • 7. Patients having deranged liver functions (AST per ALT Greater than 2 folds). Patients suffering from Hepatitis,
  • Cirrhosis of liver, Ascites, Portal hypertension (PTH), patient having other chronic liver diseases,
  • 8. Patients having deranged renal functions Or chronic kidney diseases.
  • 9. Patients suffering from AIDS, Tuberculosis and other infectious diseases.
  • 10. Any Malignancy.
  • 11. Pregnant and lactating women.
  • 12. Patient on long term medication (Hepatotoxic medication like NSAID, Rifampicin,steroid).
  • 13. Patients consuming Alcohol or other narcotic substance.

研究者

相似试验